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Purpose: Despite recent advances in donation after circulatory death, transplants from brain-dead 
donors remain the sole source in heart transplantation (HTx) worldwide. Due to organ shortage, 
marginal donors are increasingly used and the utilization of transplants becomes markedly more 
challenging. They undergo invariably brain death that induces a systemic cytokine and 
catecholamine storm that lead to systemic inflammation, labile hemodynamics, and organ 
hypoperfusion. Together, these can damage the heart and aggravate later occurring graft injury, and 
ultimately, compromise graft function. However, the effect of donor brain death on allograft is not 
well understood. 
 
Methods: In a separate prospective, blinded single-center trial, we collected donor plasma samples 
and relevant clinical patient data from 50 HTx brain-dead donors and as controls plasma samples 
from age- and gender-matched 23 healthy volunteers. Quantitative label-free proteomics in high 
definition MSE mode (HDMSE) was carried out on the samples. Various statistical analyses were 
performed on quantitative proteomics data to obtain the most reliably distinguishing proteins, which 
classify the donors vs controls. 
 
Results: With two or more unique proteins per identification, 463 proteins were quantified in our pilot 
study. A complete separation between donors and controls based on a set of 278 proteins (p-value 
<0.05) was seen in supervised and unsupervised classification techniques such as orthogonal 
projections on latent structure-discriminant analysis (OPLS-DA) and self-organizing maps. The set 
of proteins was studied further with network, pathway and protein-protein interaction analyses. Using 
OPLS-DA S-plot, we identified a protein set that completely separated donors from healthy 
individuals. 
 
Conclusion: To our knowledge, we are the first one elucidating the proteomic signature of brain-
death in human blood samples with open-label proteomics. We show that brain death alters protein 
expression, and that these changes are dependent on the donor demographics. The molecular 
pathway analyses characterize these changes in a systemic perspective. We found a set of plasma 
proteins that we suggest as a diagnostic blood biomarker panel to detect high risk heart transplants 
and we believe that we may identify novel treatment targets induced in noxious pathways after brain 
death. 
 
